ALT 0 3 0 3 B-clinical_variable
and 4 7 4 7 O
AST 8 11 8 11 B-clinical_variable
less 12 16 12 16 O
than 17 21 17 21 O
or 22 24 22 24 O
equal 25 30 25 30 O
to 31 33 31 33 O
3 34 35 34 35 B-upper_bound
x 36 37 36 37 I-upper_bound
upper 38 43 38 43 I-upper_bound
limits 44 50 44 50 I-upper_bound
of 51 53 51 53 I-upper_bound
normal 54 60 54 60 I-upper_bound

Absolute 0 8 61 69 B-clinical_variable
lymphocyte 9 19 70 80 I-clinical_variable
count 20 25 81 86 I-clinical_variable
( 26 27 87 88 I-clinical_variable
ALC 27 30 88 91 I-clinical_variable
) 30 31 91 92 I-clinical_variable
of 32 34 93 95 O
greater 35 42 96 103 O
than 43 47 104 108 O
5,000 48 53 109 114 B-lower_bound
cells 54 59 115 120 I-lower_bound
/ 59 60 120 121 I-lower_bound
microL 60 66 121 127 I-lower_bound

Age 0 3 128 131 B-age
at 4 6 132 134 O
least 7 12 135 140 O
18 13 15 141 143 B-lower_bound

Anemia 0 6 144 150 B-chronic_disease
( 7 8 151 152 O
Hgb 8 11 152 155 B-clinical_variable
less 12 16 156 160 O
than 17 21 161 165 O
10g 22 25 166 169 B-upper_bound
/ 25 26 169 170 I-upper_bound
dL 26 28 170 172 I-upper_bound
) 28 29 172 173 O

At 0 2 174 176 O
least 3 8 177 182 O
2 9 10 183 184 B-lower_bound
prior 11 16 185 190 O
courses 17 24 191 198 O
of 25 27 199 201 O
purine 28 34 202 208 O
analog 35 41 209 215 O

BMBx 0 4 216 220 B-treatment
or 5 7 221 223 O
BMA 8 11 224 227 B-treatment
consistent 12 22 228 238 O
with 23 27 239 243 O
HCL 28 31 244 247 B-cancer
, 31 32 247 248 O
confirmed 33 42 249 258 O
by 43 45 259 261 O
NIH 46 49 262 265 O
Laboratory 50 60 266 276 O
of 61 63 277 279 O
Pathology 64 73 280 289 O
, 73 74 289 290 O
NCI 75 78 291 294 O
, 78 79 294 295 O
or 80 82 296 298 O
the 83 86 299 302 O
Department 87 97 303 313 O
of 98 100 314 316 O
Laboratory 101 111 317 327 O
Medicine 112 120 328 336 O
, 120 121 336 337 O
Clinical 122 130 338 346 O
Center 131 137 347 353 O
, 137 138 353 354 O
NIH 139 142 355 358 O
, 142 143 358 359 O
unless 144 150 360 366 O
the 151 154 367 370 O
diagnosis 155 164 371 380 O
can 165 168 381 384 O
be 169 171 385 387 O
confirmed 172 181 388 397 O
from 182 186 398 402 O
a 187 188 403 404 O
solid 189 194 405 410 B-cancer
( 195 196 411 412 I-cancer
lymph 196 201 412 417 I-cancer
node 202 206 418 422 I-cancer
) 206 207 422 423 I-cancer
mass 208 212 424 428 I-cancer

Bilirubin 0 9 429 438 B-clinical_variable
less 10 14 439 443 O
than 15 19 444 448 O
or 20 22 449 451 O
equal 23 28 452 457 O
to 29 31 458 460 O
2 32 33 461 462 B-upper_bound
unless 34 40 463 469 O
consistent 41 51 470 480 O
with 52 56 481 485 O
Gilbert 57 64 486 493 B-chronic_disease
s 65 66 494 495 I-chronic_disease
( 67 68 496 497 O
total 68 73 497 502 O
/ 73 74 502 503 O
direct 74 80 503 509 O
greater 81 88 510 517 O
than 89 93 518 522 O
5 94 95 523 524 B-lower_bound
) 95 96 524 525 O

Creatinine 0 10 526 536 B-clinical_variable
less 11 15 537 541 O
than 16 20 542 546 O
or 21 23 547 549 O
equal 24 29 550 555 O
to 30 32 556 558 O
1.5 33 36 559 562 B-upper_bound
or 37 39 563 565 O
creatinine 40 50 566 576 B-clinical_variable
clearance 51 60 577 586 I-clinical_variable
greater 61 68 587 594 O
than 69 73 595 599 O
or 74 76 600 602 O
equal 77 82 603 608 O
to 83 85 609 611 O
60 86 88 612 614 B-lower_bound
ml 89 91 615 617 I-lower_bound
/ 91 92 617 618 I-lower_bound
ml 92 94 618 620 I-lower_bound

Diagnosis 0 9 621 630 O
of 10 12 631 633 O
HCL 13 16 634 637 B-cancer
variant 17 24 638 645 I-cancer
( 25 26 646 647 I-cancer
HCLv 26 30 647 651 I-cancer
) 30 31 651 652 I-cancer

ECOG 0 4 653 657 B-clinical_variable
performance 5 16 658 669 I-clinical_variable
status 17 23 670 676 I-clinical_variable
( 24 25 677 678 O
100 25 28 678 681 O
) 28 29 681 682 O
of 30 32 683 685 O
0 33 34 686 687 O
- 34 35 687 688 O
3 35 36 688 689 B-upper_bound

Efficacy 0 8 690 698 O
and/or 9 15 699 705 O
safety 16 22 706 712 O
of 23 25 713 715 O
immunization 26 38 716 728 O
during 39 45 729 735 O
periods 46 53 736 743 O
of 54 56 744 746 O
B 57 58 747 748 B-treatment
- 58 59 748 749 I-treatment
cell 59 63 749 753 I-treatment
depletion 64 73 754 763 I-treatment
have 74 78 764 768 O
not 79 82 769 772 O
been 83 87 773 777 O
adequately 88 98 778 788 O
studied 99 106 789 796 O

Enlarging 0 9 797 806 B-clinical_variable
lymph 10 15 807 812 I-clinical_variable
nodes 16 21 813 818 I-clinical_variable
greater 22 29 819 826 O
than 30 34 827 831 O
2 35 36 832 833 B-lower_bound
cm 36 38 833 835 I-lower_bound

Evidence 0 8 836 844 O
of 9 11 845 847 O
HCL 12 15 848 851 B-treatment
by 16 18 852 854 O
flow 19 23 855 859 O
cytometry 24 33 860 869 O
of 34 36 870 872 O
blood 37 42 873 878 O
or 43 45 879 881 O
a 46 47 882 883 O
solid 48 53 884 889 O
( 54 55 890 891 O
lymph 55 60 891 896 O
node 61 65 897 901 O
) 65 66 901 902 O
mass 67 71 903 907 O
, 71 72 907 908 O
confirmed 73 82 909 918 O
by 83 85 919 921 O
the 86 89 922 925 O
Laboratory 90 100 926 936 O
of 101 103 937 939 O
Pathology 104 113 940 949 O
, 113 114 949 950 O
NCI 115 118 951 954 O
, 118 119 954 955 O
including 120 129 956 965 O
positivity 130 140 966 976 O
for 141 144 977 980 O
CD19 145 149 981 985 B-clinical_variable
, 149 150 985 986 O
CD22 151 155 987 991 B-clinical_variable
, 155 156 991 992 O
CD20 157 161 993 997 B-clinical_variable
, 161 162 997 998 O
and 163 166 999 1002 O
CD11c 167 172 1003 1008 B-clinical_variable

Known 0 5 1009 1014 O
infection 6 15 1015 1024 O
with 16 20 1025 1029 O
HIV 21 24 1030 1033 B-chronic_disease
, 24 25 1033 1034 O
hepatitis 26 35 1035 1044 B-chronic_disease
B 36 37 1045 1046 I-chronic_disease
or 38 40 1047 1049 I-chronic_disease
C 41 42 1050 1051 I-chronic_disease

Men 0 3 1052 1055 B-gender

Neutropenia 0 11 1056 1067 B-chronic_disease
( 12 13 1068 1069 O
ANC 13 16 1069 1072 B-clinical_variable
less 17 21 1073 1077 O
than 22 26 1078 1082 O
1000 27 31 1083 1087 B-upper_bound
cells 32 37 1088 1093 I-upper_bound
/ 37 38 1093 1094 I-upper_bound
microl 38 44 1094 1100 I-upper_bound
) 44 45 1100 1101 O

No 0 2 1102 1104 O
other 3 8 1105 1110 O
therapy 9 16 1111 1118 B-treatment
( 17 18 1119 1120 O
i.e. 18 22 1120 1124 O
chemotherapy 23 35 1125 1137 B-treatment
, 35 36 1137 1138 O
interferon 37 47 1139 1149 B-treatment
) 47 48 1149 1150 O
for 49 52 1151 1154 O
4 53 54 1155 1156 B-upper_bound
weeks 55 60 1157 1162 I-upper_bound
prior 61 66 1163 1168 I-upper_bound
to 67 69 1169 1171 O
study 70 75 1172 1177 O
entry 76 81 1178 1183 O

Patients 0 8 1184 1192 O
who 9 12 1193 1196 O
are 13 16 1197 1200 O
considered 17 27 1201 1211 O
to 28 30 1212 1214 O
be 31 33 1215 1217 O
at 34 36 1218 1220 O
high 37 41 1221 1225 O
risk 42 46 1226 1230 O
for 47 50 1231 1234 O
hepatitis 51 60 1235 1244 B-chronic_disease
B 61 62 1245 1246 I-chronic_disease
virus 63 68 1247 1252 I-chronic_disease
( 69 70 1253 1254 I-chronic_disease
HBV 70 73 1254 1257 I-chronic_disease
) 73 74 1257 1258 I-chronic_disease
infection 75 84 1259 1268 I-chronic_disease
and 85 88 1269 1272 O
for 89 92 1273 1276 O
whom 93 97 1277 1281 O
the 98 101 1282 1285 O
investigator 102 114 1286 1298 O
has 115 118 1299 1302 O
determined 119 129 1303 1313 O
that 130 134 1314 1318 O
immunization 135 147 1319 1331 O
is 148 150 1332 1334 O
indicated 151 160 1335 1344 O
should 161 167 1345 1351 O
complete 168 176 1352 1360 O
the 177 180 1361 1364 O
entire 181 187 1365 1371 O
HBV 188 191 1372 1375 B-treatment
vaccine 192 199 1376 1383 I-treatment
series 200 206 1384 1390 O
at 207 209 1391 1393 O
least 210 215 1394 1399 O
4 216 217 1400 1401 B-lower_bound
weeks 218 223 1402 1407 I-lower_bound
prior 224 229 1408 1413 I-lower_bound
to 230 232 1414 1416 O
participation 233 246 1417 1430 O
in 247 249 1431 1433 O
the 250 253 1434 1437 O
study 254 259 1438 1443 O

Patients 0 8 1444 1452 O
with 9 13 1453 1457 O
flow 14 18 1458 1462 O
cytometry 19 28 1463 1472 B-clinical_variable
consistent 29 39 1473 1483 O
with 40 44 1484 1488 O
HCL 45 48 1489 1492 B-cancer
variant 49 56 1493 1500 I-cancer
( 57 58 1501 1502 I-cancer
HCLv 58 62 1502 1506 I-cancer
) 62 63 1506 1507 I-cancer
are 64 67 1508 1511 O
eligible 68 76 1512 1520 O
, 76 77 1520 1521 O
including 78 87 1522 1531 O
those 88 93 1532 1537 O
with 94 98 1538 1542 O
CD25 99 103 1543 1547 B-treatment
and/or 104 110 1548 1554 O
CD103 111 116 1555 1560 B-treatment
negative 117 125 1561 1569 O
disease 126 133 1570 1577 O

Patients 0 8 1578 1586 O
with 9 13 1587 1591 O
history 14 21 1592 1599 O
of 22 24 1600 1602 O
non 25 28 1603 1606 O
- 28 29 1606 1607 O
response 29 37 1607 1615 O
to 38 40 1616 1618 O
both 41 45 1619 1623 O
pentostatin 46 57 1624 1635 B-treatment
plus 58 62 1636 1640 O
rituximab 63 72 1641 1650 B-treatment
and 73 76 1651 1654 O
to 77 79 1655 1657 O
bendamustine 80 92 1658 1670 B-treatment
plus 93 97 1671 1675 O
rituximab 98 107 1676 1685 O

Pregnant 0 8 1686 1694 B-pregnancy

Presence 0 8 1695 1703 O
of 9 11 1704 1706 O
CNS 12 15 1707 1710 B-chronic_disease
disease 16 23 1711 1718 I-chronic_disease

Presence 0 8 1719 1727 O
of 9 11 1728 1730 O
active 12 18 1731 1737 O
2nd 19 22 1738 1741 O
malignancy 23 33 1742 1752 B-cancer
requiring 34 43 1753 1762 O
treatment 44 53 1763 1772 B-treatment

Presence 0 8 1773 1781 O
of 9 11 1782 1784 O
active 12 18 1785 1791 O
untreated 19 28 1792 1801 O
infection 29 38 1802 1811 B-chronic_disease

Receipt 0 7 1812 1819 O
of 8 10 1820 1822 O
a 11 12 1823 1824 O
live 13 17 1825 1829 B-treatment
vaccine 18 25 1830 1837 I-treatment
within 26 32 1838 1844 O
4 33 34 1845 1846 B-upper_bound
weeks 35 40 1847 1852 I-upper_bound
prior 41 46 1853 1858 I-upper_bound
to 47 49 1859 1861 O
randomization 50 63 1862 1875 O

Repeated 0 8 1876 1884 O
infections 9 19 1885 1895 O
requiring 20 29 1896 1905 O
oral 30 34 1906 1910 B-treatment
or 35 37 1911 1913 O
i.v 38 41 1914 1917 B-treatment
. 41 42 1917 1918 I-treatment
antibiotics 43 54 1919 1930 I-treatment

Review 0 6 1931 1937 O
of 7 9 1938 1940 O
the 10 13 1941 1944 O
patient 14 21 1945 1952 O
s 22 23 1953 1954 O
immunization 24 36 1955 1967 B-treatment
status 37 43 1968 1974 O
for 44 47 1975 1978 O
the 48 51 1979 1982 O
following 52 61 1983 1992 O
vaccinations 62 74 1993 2005 B-treatment
is 75 77 2006 2008 O
recommended 78 89 2009 2020 O
: 89 90 2020 2021 O
tetanus 91 98 2022 2029 B-treatment
; 98 99 2029 2030 O
diphtheria 100 110 2031 2041 B-treatment
; 110 111 2041 2042 O
influenza 112 121 2043 2052 B-treatment
; 121 122 2052 2053 O
Pneumococcal 123 135 2054 2066 B-treatment
polysaccharide 136 150 2067 2081 I-treatment
; 150 151 2081 2082 O
Varicella 152 161 2083 2092 B-treatment
; 161 162 2092 2093 O
measles 163 170 2094 2101 B-treatment
, 170 171 2101 2102 O
mumps 172 177 2103 2108 B-treatment
and 178 181 2109 2112 O
rubella 182 189 2113 2120 B-treatment
( 190 191 2121 2122 I-treatment
MMR 191 194 2122 2125 I-treatment
) 194 195 2125 2126 I-treatment
; 195 196 2126 2127 O
and 197 200 2128 2131 O
hepatitis 201 210 2132 2141 B-treatment
B 211 212 2142 2143 I-treatment

Symptomatic 0 11 2144 2155 O
splenomegaly 12 24 2156 2168 B-chronic_disease

The 0 3 2169 2172 O
patient 4 11 2173 2180 O
may 12 15 2181 2184 O
have 16 20 2185 2189 O
any 21 24 2190 2193 O
required 25 33 2194 2202 O
vaccination 34 45 2203 2214 B-treatment
/ 45 46 2214 2215 O
booster 46 53 2215 2222 B-treatment
administered 54 66 2223 2235 O
at 67 69 2236 2238 O
least 70 75 2239 2244 O
4 76 77 2245 2246 B-lower_bound
weeks 78 83 2247 2252 I-lower_bound
prior 84 89 2253 2258 I-lower_bound
to 90 92 2259 2261 O
the 93 96 2262 2265 O
initiation 97 107 2266 2276 O
of 108 110 2277 2279 O
study 111 116 2280 2285 B-treatment
treatment 117 126 2286 2295 I-treatment

Thrombocytopenia 0 16 2296 2312 B-chronic_disease
( 17 18 2313 2314 O
Plt 18 21 2314 2317 B-clinical_variable
less 22 26 2318 2322 O
than 27 31 2323 2327 O
100,000 32 39 2328 2335 B-upper_bound
/ 39 40 2335 2336 I-upper_bound
microl 40 46 2336 2342 I-upper_bound
) 46 47 2342 2343 O

Treatment 0 9 2344 2353 B-treatment
indicated 10 19 2354 2363 O
based 20 25 2364 2369 O
on 26 28 2370 2372 O
demonstration 29 42 2373 2386 O
of 43 45 2387 2389 O
at 46 48 2390 2392 O
least 49 54 2393 2398 O
one 55 58 2399 2402 B-lower_bound
of 59 61 2403 2405 O
the 62 65 2406 2409 O
following 66 75 2410 2419 O
no 76 78 2420 2422 O
more 79 83 2423 2427 O
than 84 88 2428 2432 O
4 89 90 2433 2434 O
weeks 91 96 2435 2440 O
from 97 101 2441 2445 O
the 102 105 2446 2449 O
time 106 110 2450 2454 O
of 111 113 2455 2457 O
enrollment 114 124 2458 2468 O
, 124 125 2468 2469 O
and 126 129 2470 2473 O
no 130 132 2474 2476 O
less 133 137 2477 2481 O
than 138 142 2482 2486 O
6 143 144 2487 2488 B-lower_bound
months 145 151 2489 2495 I-lower_bound
after 152 157 2496 2501 O
prior 158 163 2502 2507 B-treatment
cladribine 164 174 2508 2518 I-treatment
and 175 178 2519 2522 O
no 179 181 2523 2525 O
less 182 186 2526 2530 O
than 187 191 2531 2535 O
4 192 193 2536 2537 O
weeks 194 199 2538 2543 O
after 200 205 2544 2549 O
other 206 211 2550 2555 O
prior 212 217 2556 2561 B-treatment
treatment 218 227 2562 2571 I-treatment

Uncontrolled 0 12 2572 2584 O
coronary 13 21 2585 2593 B-chronic_disease
disease 22 29 2594 2601 I-chronic_disease
or 30 32 2602 2604 O
NYHA 33 37 2605 2609 B-clinical_variable
class 38 43 2610 2615 B-lower_bound
III 44 47 2616 2619 I-lower_bound
- 47 48 2619 2620 O
IV 48 50 2620 2622 B-upper_bound
heart 51 56 2623 2628 B-chronic_disease
disease 57 64 2629 2636 I-chronic_disease

Unmutated 0 9 2637 2646 B-clinical_variable
( 10 11 2647 2648 O
> 11 12 2648 2649 O
98 12 14 2649 2651 B-lower_bound
% 14 15 2651 2652 I-lower_bound
homology 16 24 2653 2661 O
to 25 27 2662 2664 O
germline 28 36 2665 2673 O
) 36 37 2673 2674 O
IGHV4 38 43 2675 2680 O
- 43 44 2680 2681 O
34+expressing 44 57 2681 2694 O
HCL 58 61 2695 2698 O
/ 61 62 2698 2699 O
HCLv 62 66 2699 2703 O

agree 0 5 2704 2709 B-contraception_consent
to 6 8 2710 2712 I-contraception_consent
use 9 12 2713 2716 I-contraception_consent
an 13 15 2717 2719 I-contraception_consent
acceptable 16 26 2720 2730 I-contraception_consent
method 27 33 2731 2737 I-contraception_consent
of 34 36 2738 2740 I-contraception_consent
birth 37 42 2741 2746 I-contraception_consent
control 43 50 2747 2754 I-contraception_consent
during 51 57 2755 2761 O
treatment 58 67 2762 2771 B-treatment
and 68 71 2772 2775 O
for 72 75 2776 2779 O
twelve 76 82 2780 2786 O
months 83 89 2787 2793 O
after 90 95 2794 2799 O
completion 96 106 2800 2810 O
of 107 109 2811 2813 O
treatment 110 119 2814 2823 O

cladribine 0 10 2824 2834 B-treatment
for 11 14 2835 2838 O
6 15 16 2839 2840 B-upper_bound
months 17 23 2841 2847 I-upper_bound
prior 24 29 2848 2853 I-upper_bound
to 30 32 2854 2856 O
study 33 38 2857 2862 O
entry 39 44 2863 2868 O

lactating 0 9 2869 2878 O
women 10 15 2879 2884 B-gender

women 0 5 2885 2890 B-gender
of 6 8 2891 2893 O
reproductive 9 21 2894 2906 O
potential 22 31 2907 2916 O

